Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc. is projected to generate approximately $32 million in top-line revenue for 2025, with expectations of a significant increase to $130.4 million by 2026, indicating strong growth potential. The favorable market access situation suggests that coverage for its gene therapies and plasma-based products is likely to improve, which may drive additional revenue upside. Furthermore, the company's promising pipeline assets, specifically its innovative gene therapies targeting rare genetic diseases, may further enhance the positive outlook on its financial performance.

Bears say

Abeona Therapeutics Inc. faces significant risks that negatively impact its outlook, particularly the potential for slower-than-expected market uptake of its engineered cell therapy, pz-cel, in the United States. The company's challenges extend to its inability to maximize the value of pz-cel outside the U.S., which could hinder revenue growth. Furthermore, setbacks in earlier-stage pipeline programs and the prospect of long-term dilution add additional layers of uncertainty to the financial viability of the company.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.